Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients

European Journal of Cancer

Volumn 41, Issue 1, 2005, Pages 118-125

  Kolmel K F ^a   Grange, J M ^b   Krone, B ^a   Mastrangelo, G ^c   Rossi, C R ^c   Henz, B M ^d   Seebacher, C ^e   Botev, I N ^f   Niin, M ^g   Lambert, D ^h   Shafir, R ⁱ   Kokoschka, E M ^j   Kleeberg, U R ^k   Gefeller, O ^l   Pfahlberg, A ^l  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d HUMBOLDT UNIVERSITY   (Germany)

^e ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^f UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^g Estonian Cancer Centre   (Estonia)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^k Int Oncol and Laboratory Medicine   (Germany)

^l UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

more..

Author keywords

BCG; Immunisation; Melanoma; Survival; Vaccinia

Indexed keywords

BCG VACCINE; CANCER VACCINE; VACCINIA VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; CANCER CONTROL; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFECTION COMPLICATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; COHORT STUDIES; FEMALE; HUMANS; IMMUNIZATION; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SMALLPOX VACCINE; SURVIVAL ANALYSIS; VACCINATION; VACCINIA;

EID: 19944383121     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.09.023     Document Type: Article

References (17)

1. J.L. Stanford, C.A. Stanford, and J.M. Grange Environmental echoes Sci Prog 84 Part 2 2001 105 124
2. G.A. Rook, and L.R. Brunet Give us this day our daily germs Biologist 49 2002 145 149
3. P.G. Holt Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution Pediatr Allergy Immun 6 1995 1 10
4. F.D. Martinez, and P.G. Holt Role of microbial burden in aetiology of allergy and asthma Lancet 354 suppl II 1999 12 15
5. S.L. Prescott, C. Macaubas, and T. Smallacombe Development of allergen-specific T-cell memory in atopic and normal children Lancet 353 1999 196 200
6. U. Abel, N. Becker, and R. Angerer Common infections in the history of cancer patients and controls J Cancer Res Clin Oncol 117 1991 339 344
7. F. Perrillat, J. Clavel, and M.F. Auclerc Day-care, early common infections and childhood acute leukaemia: a multicentre French case-control study Br J Cancer 86 2002 1064 1069
8. X. Ma, P.A. Buffler, and S. Selvin Daycare attendance and risk of childhood acute lymphoblastic leukaemia Br J Cancer 86 2002 1419 1424
9. K.F. Kölmel, O. Gefeller, and B. Haferkamp Febrile infections and malignant melanoma: results of a case-control study Melanoma Res 2 1992 207 211
10. K.F. Kölmel, A. Pfahlberg, and G. Mastrangelo Infections and melanoma risk: results of a multicentre EORTC case-control study Melanoma Res 9 1999 511 519
11. A. Pfahlberg, K.F. Kölmel, and J.M. Grange Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study J Invest Dermatol 119 2002 570 575
12. B. Krone, K.F. Kölmel, and J.M. Grange Impact of vaccinations and infectious diseases on the risk of melanoma - evaluation of an EORTC case-control-study Eur J Cancer 39 2003 2372 2378
13. D.A. Grimes, and K.F. Schulz Cohort studies. Marching towards outcomes Lancet 359 2002 341 345
14. J.M. Thomas, J. Newton-Bishop, and R. A'Hern Excision margins in high-risk malignant melanoma N Engl J Med 350 2004 757 766
15. C.M. Balch, S.-.J. Soong, and J.E. Gershenwald Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System J Clin Oncol 19 2001 3622 3634
16. G. Weinlich, W. Bitterlich, V. Mayr, P.O. Fritsch, and B. Zelger Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients Br J Dermatol 149 2003 535 541
17. J.M. Grange, J.L. Stanford, and C.A. Stanford Campbell De Morgan's 'Observations on cancer', and their relevance today J R Soc Med 95 2002 296 299